Benzinga | Apr 28, 2021 10:25AM EDT

Immutep Says To Announce New TACTI-002 And INSIGHT-004 Data In Poster Presentations and Discussion At ASCO 2021 Annual Meeting; Shares Move Higher

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology's (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 -- 8 June.

Abstracts will be available from 5pm US Eastern Time on 19 May 2021. Poster presentations with new and updated data that are not part of the abstract will be released on ASCO.org at the times indicated below and will subsequently be made available on Immutep's website at www.immutep.com.

In addition, Immutep plans to hold a webcast after ASCO to discuss the data and results, as well as to provide an update on the Company's business.

TACTI-002 Posters Results from a phase II study of eftilagimod alpha (soluble LAG-3Title: protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.Session Poster Session: Lung Cancer - Non-Small Cell MetastaticTitle:Date: On demand session available from 9am on 4 June 2021 US Eastern TimePresenter: Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, AustraliaAbstract: 9046 Results from a phase II study of eftilagimod alpha (soluble LAG-3Title: protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.Session Poster Session: Head and Neck CancerTitle:Date: On demand session available from 9am on 4 June 2021 US Eastern TimePresenter: Dr Irene Brana, Investigator, Vall d'Hebron Institute of Oncology, Barcelona, SpainAbstract: 6028INSIGHT-004 Poster Phase I INSIGHT platform trial: Advanced safety and efficacy dataTitle: from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.Session Poster Discussion Session, Developmental Therapeutics -Title: ImmunotherapyDate: On demand session available from 9am on 4 June 2021 US Eastern Time Thorsten Oliver Goetze, MD; Krankenhaus Nordwest, University CancerPresenter: Center Frankfurt and Institut fu:r Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, GermanyAbstract: 2518

About American Society of Clinical Oncology (ASCO) Conference

ASCO's annual meeting represents the world's largest gathering of oncology physicians, industry representatives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care. For additional information on the 2021 ASCO's Annual meeting, please visit https://www.asco.org/

About TACTI-002

TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada). The study is evaluating the combination of efti with MSD's KEYTRUDA(r) (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

About INSIGHT-004 (also known as INSIGHT Stratum D)

INSIGHT-004 is a Phase I clinical trial and is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immutep's collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialised by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

About Immutep